27.75

1.80% -0.51

After Hours: 27.77 0.02 +0.07%

Oculis Holding Ag (OCS)

Overview News Price History Discussions Forecast

Oculis Holding Ag stock is traded at $27.75, with a volume of 413.25K. It is down -1.80% in the last 24 hours and up +4.21% over the past month. Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Previous Close:

$28.26

Open:

$28.6

24h Volume:

413.25K

Relative Volume:

1.18

Market Cap:

$1.61B

Revenue:

Net Income/Loss:

$-118.12M

P/E Ratio:

-12.17

EPS:

-2.2802

Net Cash Flow:

$-82.63M

1W Performance:

+3.85%

1M Performance:

+4.21%

6M Performance:

+43.56%

1Y Performance:

+49.43%

1-Day Range:

$27.63

$29.05

1-Week Range:

$25.91

$29.05

52-Week Range:

$16.00

$30.68

Oculis Holding Ag Stock (OCS) Company Profile

Name

Oculis Holding Ag

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

OCS's Discussions on Twitter

Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCS Oculis Holding Ag	27.75	1.64B	0	-118.12M	-82.63M	-2.2802
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Oculis Holding Ag Stock (OCS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-25	Initiated	JP Morgan	Overweight
Aug-27-25	Initiated	Needham	Buy
Dec-05-23	Initiated	Chardan Capital Markets	Buy
Oct-05-23	Initiated	Stifel	Buy
Jun-14-23	Initiated	BofA Securities	Buy
Jun-12-23	Initiated	H.C. Wainwright	Buy
Jun-08-23	Initiated	Robert W. Baird	Outperform
May-10-23	Initiated	Pareto	Buy
Apr-28-23	Initiated	Wedbush	Outperform

View All

Oculis Holding Ag Stock (OCS) Latest News

04:00 AM

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting - GlobeNewswire

04:00 AM

May 02, 2026

Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes - TipRanks

May 02, 2026

H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com

May 02, 2026

Gildi lifeyrissjodur Makes New Investment in Oculis Holding AG $OCS - MarketBeat

May 02, 2026

May 01, 2026

Oculis Highlights Innovative Late-Stage Pipeline and Unmet Needs in Diabetic Macular Edema at ARVO 2026 - Quiver Quantitative

May 01, 2026

June eye-drop data nears as Oculis brings DME, optic neuritis studies - Stock Titan

May 01, 2026

LSP 7 holds 6.95M shares in Oculis Holding (OCS) as of Mar 31, 2026 - Stock Titan

Apr 29, 2026

Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors? - Yahoo Finance

Apr 29, 2026

Apr 27, 2026

Oculis reports final phase 3 patient visit for DME eye drops - Eyes On Eyecare

Apr 27, 2026

Apr 26, 2026

Assessing Oculis Holding (OCS) Valuation As DIAMOND Phase 3 Trials Reach Key Completion Milestone - simplywall.st

Apr 26, 2026

Apr 25, 2026

Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing - TipRanks

Apr 25, 2026

(OCS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Apr 25, 2026

Apr 21, 2026

Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session - TipRanks

Apr 21, 2026

Oculis (Nasdaq: OCS) sets 2026 AGM, details late-stage pipeline and expanded share capital tools - Stock Titan

Apr 21, 2026

Oculis Publishes Invitation to the Annual General Meeting - GlobeNewswire

Apr 21, 2026

Oculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Apr 21, 2026

Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 21, 2026

H.C. Wainwright reiterates Oculis stock rating on trial completion By Investing.com - Investing.com Australia

Apr 21, 2026

Why Oculis Holding (OCS) Is Up 5.5% After Phase 3 DME Trial Milestone – And What's Next - simplywall.st

Apr 21, 2026

Apr 20, 2026

OCS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus

Apr 20, 2026

Oculis completes final patient visit in OCS-01 phase 3 trial in DME - Ophthalmology Times

Apr 20, 2026

HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat

Apr 20, 2026

Oculis Holding AG Announces Completion of Last Patient Visit in Phase 3 Diamond Program with OCS-01 Eye Drops for Treatment of Diabetic Macular Edema - marketscreener.com

Apr 20, 2026

Oculis Completes Last Patient Visits in Phase 3 DIAMOND Trials for OCS-01, Anticipates Topline Results in June 2026 - Quiver Quantitative

Apr 20, 2026

800+ patients finish Oculis diabetic eye-drop trials before June data - Stock Titan

Apr 20, 2026

Oculis Announces Completion of Last Patient Visit in Phase - GlobeNewswire

Apr 20, 2026

Apr 17, 2026